Abstract #4178

Is Serial MR Spectroscopy Revealing an Anti-Tumor Effect of Cediranib in Human Glioblastoma?

Heisoog Kim^1,2, Ciprian Catana², Eva-Maria Ratai², Wei-Ting Zhang², Priscilla Yeo², Ovidiu Cristian Andronesi², Tracy T. Batchelor³, Rakesh K. Jain⁴, A. Gregory Sorensen²

¹NSE/HST, Massachusetts Institute of Technology, Cambridge, MA, USA; ²Radiology, Massachusetts General Hospital, Boston, MA, USA; ³Neurology, Massachusetts General Hospital, Boston, MA, USA; ⁴Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA

This study evaluated the predominant metabolites changes in 1H-MRS to provide supplementary information understanding the response of cancerous tissue to the anti-angiogenic agent in patients with recurrent malignant glioblastoma. After one dose, NAA/norCre and Cho/norCre in eleven positive-responding patients showed a significant increase in ET. Also, NAA/norCre and Cho/norCre measured in all twenty patients showed significant changes at day 28, and at day 112, the trend was reversed, an increase of Cho and a decrease of NAA. By evaluating the early changes in the predominant metabolites, it would reveal a pharmacologic effect of cedrinib.